Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Syntrix Biosystems Inc (AKA: Syntrix Biochip Inc~Syntrix Inc)
Profile last edited on: 5/14/2019      CAGE: 4PR79      UEI: L5Z8K6ZE8LY4

Business Identifier: Biopharmaceutical focused on unmet markets
Year Founded
1999
First Award
2001
Latest Award
2021
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

215 Clay Street Nw Suite B-5
Auburn, WA 98001
   (253) 833-8009
   info@syntrixbio.com
   www.syntrixbio.com
Location: Single
Congr. District: 09
County: King

Public Profile

Syntrix Biosystems is dedicated to developing and commercializing therapeutic compounds and research platforms for the pharmaceutical, biotechnology and research markets. Syntrix has two drugs for pain and pulmonary disease in the pipeline. In 2015, the phase 1B study investigating Omnitram for pain in healthy subjects met its primary endpoints for pharmacokinetics, safety, and analgesia. The firm is also expanding through both in-house development and strategic acquisitions and partnerships to other disease areas where there are unmet needs.

Extent of SBIR involvement

User Avatar
Phase I Awards
21
Phase II Awards
18
Conversion Rate
85.71%
Phase I Dollars
$6,400,902
Phase II Dollars
$28,546,758
Total Awarded
$34,947,660

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
15-19

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2021 2 NIH $1,489,433
Project Title: A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects
2021 2 NIH $2,299,999
Project Title: A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and with Pembrolizumab in Metastatic Melanoma
2020 2 NIH $3,398,342
Project Title: HLS- a Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients
2018 2 NIH $1,668,788
Project Title: Efficacy and Resistance Mechanisms of LD-Aminopterin in Psoriasis
2018 2 NIH $5,597,786
Project Title: Overcoming Tramadol Resistance in Cyp2d6 Poor Metabolizers

Key People / Management

  John A Zebala -- President, Chief Executive Officer

  Stuart J Kahn -- Medical Director

  Dean Y Maeda -- Director of Chemistry and Preclinical Development

  Joel Morgan

  Aaron D Schuler -- Research Scientist

Company News

Nov 06 2013
Court Upholds $115 Million Judgment in Patent Case Filed by Syntrix Biosystems against Illumina, Inc.